

BLA 761473

BLA APPROVAL

Formycon AG
c/o SDDS, LLC
Attention: Scott A. Oglesby
Principal Consultant
6518 Green Rise Road
Hillsborough, NC 27278

Dear Scott A. Oglesby:

Please refer to your biologics license application (BLA) received December 27, 2024, and your amendments, submitted under section 351(k) of the Public Health Service Act for Nufymco (ranibizumab-leyk) injection.

This BLA seeks licensure of Nufymco (ranibizumab-leyk) as biosimilar to and interchangeable with US-Lucentis (ranibizumab) as follows:

- Nufymco (ranibizumab-leyk) 0.3 mg (0.05 mL of 6 mg/mL) injection, for intravitreal use in a single-dose glass vial as biosimilar to and interchangeable with US-Lucentis (ranibizumab) 0.3 mg (0.05 mL of 6 mg/mL) injection, for intravitreal use in a single-dose prefilled syringe (PFS).
- Nufymco (ranibizumab-leyk) 0.5 mg (0.05 mL of 10 mg/mL) injection, for intravitreal use in a single-dose glass vial as biosimilar to and interchangeable with US-Lucentis (ranibizumab) 0.5 mg (0.05 mL of 10 mg/mL) injection, for intravitreal use in a single-dose PFS.

LICENSING

We have approved your BLA for Nufymco (ranibizumab-leyk) injection effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Nufymco under your existing Department of Health and Human Services U.S. License No. 2322.

Nufymco is indicated for:

- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Myopic Choroidal Neovascularization (mCNV)

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture Nufymco drug substance at (b) (4) The final formulated vial drug product will

be manufactured, filled, labeled, and packaged at (b) (4)
(b) (4) You may label your product with the proprietary name, Nufymco, and market it in a vial presentation at 6 mg/mL and 10 mg/mL solutions for intravitreal injection.

DATING PERIOD

The dating period for Nufymco shall be 36 months from the date of manufacture when stored at 5 °C ± 3 °C, protected from light, for the vial presentation. The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product.

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Nufymco and each kit component to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Nufymco, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As (October 2009)*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and**

¹ See <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

Container Labeling for approved BLA 761473. Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your supplemental application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 601.12(f)(4)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements at 21 CFR 600.80.

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements at 21 CFR 600.81.

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.

If you have any questions, contact Michael Puglisi, Senior Regulatory Project Manager via email at michael.puglisi@fda.hhs.gov or call 301-796-0791.

Sincerely,

{See appended electronic signature page}

William M. Boyd, MD
Director
Division of Ophthalmology
Office of Specialty Medicine
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

WILLIAM M BOYD
12/18/2025 01:27:50 PM